• ‘Secret Shares’ of Patient Health Data Enable Secure Multiparty Research

    Nov 20 | Bio-IT World | Scientists in Europe collaborated on the first international-level clinical study using secure multiparty computation (MPC), which enabled cross-border cooperation without sharing any personalized health data. The cryptographic method traces back to the late 1970s but has been “severely underused” up until now because it’s computationally complex and few data security experts are familiar with the technology. More

  • Recursion, Novo Nordisk Release New Chemistry Foundation Model

    Nov 19 | Bio-IT World | In a paper published last week in Nature Communications, teams from Recursion and Novo Nordisk created a new foundation model for chemistry called MolE. Benchmarked for absorption, distribution, metabolism, excretion, and toxicity (ADMET) using the Therapeutic Data Commons, MolE outperformed previous models. More

  • Much Like a Crime Scene, Cancer’s Evolution Can be Reconstructed

    Nov 14 | Bio-IT World | Investigators at Weill Cornell Medicine have combined several powerful technologies to reconstruct how cancer spreads from the prostate to metastatic sites elsewhere in the body. Bioluminescence imaging, CRISPR/Cas9-based barcoding, and innovative computational methods for tracing the movement of cancer from tissue to tissue were used in creating a roadmap revealing the small number of aggressive cells that seed cancer’s often deadly migration. More

  • Blueprint of the Human Spliceosome Could Help Find Cancer’s Achilles’ Heel

    Nov 13 | Bio-IT World | The spliceosome, the cellular machinery that catalyzes the process of splicing in genes, was discovered nearly five decades ago and has been successfully leveraged in the development of therapies for rare diseases such as spinal muscular dystrophy where concerns about side effects tend to be secondary to correcting the underlying pathology. The question now is how to move the strategy to more complex diseases involving more than a single gene and splicing mutation. More

  • New Diagnostic Tool for Identifying the Effects of Antifibrotic Therapy in Breast Cancer

    Nov 12 | Bio-IT World | In recent research, scientists at the University of Arizona have developed a diagnostic tool, the MeCo Score, which evaluates metastatic risk in early-stage breast cancer by analyzing how cancer cells respond to the stiffness of surrounding tissue. This tool leverages RNA sequencing data from tumor samples to identify a "mechanical conditioning" (MeCo) signature, giving insights into cancer cell adaptations within the tumor microenvironment. More

  • Foundations for Change: A Framework for Transforming R&D Outcomes With AI

    Nov 08 | Bio-IT World | For AI and data-driven drug discovery to have a tangible impact on R&D success, a change in the culture is as important as any investment at a data, model, and validation level. Until quite recently, the perceived value of AI in drug discovery and development failed to match the hype. More

  • PacBio’s Pink Desktop Platform, $500 Genome Chemistry

    Nov 07 | Bio-IT World | This week at the American Society of Human Genetics meeting, Pacific Biosciences unveiled both its new SPRQ chemistry—pronounced “spark”— and its newest sequencing platform, Vega, a desktop, long-read sequencer with all the compute on board. Also it’s pink. More

  • New Data Suggests a More Expansive View of Heart Health Lipids

    Nov 04 | Bio-IT World | The traditional LDL and HDL cholesterol tests may soon be obsolete as new research suggests they provide an incomplete view of heart health compared to other lipid molecules circulating in the blood. This shift stems from a recent study led by Dr. Cristina Legido-Quigley, a systems medicine expert at King’s College London and Steno Diabetes Centre, which analyzed lipids in children with obesity. More

  • AI Points to Drug Repurposing Opportunities for Diseases Without Cures

    Oct 31 | Bio-IT World | Harvard scientists have succeeded in using artificial intelligence (AI) to identify promising drug candidates for diseases for which there are no examples of successful treatment. The graph foundation model, known as TxGNN, opens untold opportunities to repurpose drugs for the thousands of diseases afflicting small populations and exacting a huge toll in terms of both economics and human suffering. More

  • New 10x Instruments, Merck Acquires Modifi Biosciences, New Immunogenicity Bioanalysis Features, Partnerships, More

    Oct 30 | Bio-IT World | Modifi Biosciences has been acquired by Merck; Sapio Sciences announces the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform; and more. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!